[ Tips ] 一分鐘使用導覽
商品編號： 9-626-016 出版日期： 2025/07/14 作者姓名： Li, Michael Lingzhi;Mao Fu, Brian;Chan, Billy 商品類別： Operations management 商品規格： 14p 再版日期： 2025/10/14 地域： Hong Kong SAR;Massachusetts;New York 產業： Pharmaceutical industry 個案年度： -
商品敘述：
In 2024, the AI biotech firm Insilico Medicine faced a pivotal decision about its new drug, Rentosertib. Discovered and designed using artificial intelligence to treat a lung disease, Rentosertib had successfully advanced to Phase II trials - a first in global pharmaceutical history. Insilico could license the drug, consistent with its low-risk, revenue-generating model, or continue internal development to validate its full-stack AI capabilities. The decision would shape not only the future of Rentosertib, but also how Insilico balanced risk and ambition in deploying its AI tools-defining its identity as either a bold full-stack clinical innovator or a disciplined pioneer in early-stage discovery.
涵蓋領域：
AI and machine learning
相關資料：
哪些人也有訂購？